Sinopharm Group (1099) Q4 2023 earnings summary

Executive summary

• Revenue reached RMB596,570 million in 2023, up 8.05% YoY; net profit rose 4.63% to RMB15,010 million.

• Market share increased, maintaining a stable leading industry position.

Financial highlights

• Net profit attributable to owners of the parent rose 6.19% YoY to RMB9,054 million.

• Operating cash flow was RMB17,173.03 million, down from RMB20,963.78 million in 2022.

• Revenue mix remained led by pharmaceutical distribution at 71.25%, followed by medical device distribution at 21.09% and retail pharmacy at 5.78%.

Outlook and guidance

• Priorities include expanding hospital, county-level medical community and terminal networks; increasing high-clinical-value products and value-added supply-chain services.

• Plans include professional marketing services, stronger pharmaceutical-device synergies, and growth in device manufacturing and industrial R&D.

• Retail strategy targets differentiated pharmacy formats, network optimization, dual-channel and outpatient retail opportunities, and improved profitability.

• Digital transformation, integrated provincial platforms, receivables management and liquidity controls are key operating priorities.